Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Details for Australian Patent Application No. 2005326149 (hide)

International Classifications

Event Publications

2 August 2007 PCT application entered the National Phase

PCT publication WO2006/080920 Priority application(s): WO2006/080920

4 June 2009 Assignment before Grant

Vicuron Pharmaceuticals Inc. The application has been assigned to NAICONS s.c.a.r.l

29 October 2009 Application Accepted

Published as AU-B-2005326149

10 December 2009 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 11 Nov 2009. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

1 April 2010 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 11 Nov 2009

8 April 2010 Standard Patent Sealed

1 July 2010 Assignment Registered

NAICONS s.c.a.r.l The patent has been assigned to NexThera Biosciences S.r.l.

15 July 2010 Assignment Registered

NexThera Biosciences S.r.l. The patent has been assigned to Sentinella Pharmaceuticals, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.